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Abstract
Despite the introduction of complex pharmacological approaches, heart failure (HF) is still a therapeutic challenge, 
especially when it is associated with type 2 diabetes mellitus (T2DM). Recently, large clinical trials have shown multiple 
benefits from using sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 agonists not only in the field 
of diabetes but also as agents reducing the risk of cardiovascular events and the frequency of hospitalisation due to HF 
deterioration. This has been reflected in the recent American Heart Association (ACC) 2018 guidelines for risk reduction 
in patients with T2DM and cardiovascular diseases, and in the ACC/American Heart Association (AHA) 2019 guidelines 
for primary prevention of cardiovascular diseases.
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Introduction
Heart failure (HF) continues to be a significant clinical 
and socio-economic problem, despite an increased under-
standing of its causes and diverse treatment approaches. 
Although many new compounds have appeared promising 
in the treatment of HF, most have proved ineffective. Owing 
to economic factors, existing compounds have been studied 
with the aim of using them for novel indications.
The co-occurrence of HF with type 2 diabetes mellitus 
(T2DM) worsens a patient’s prognosis and increases the 
risk of cardiovascular events and hospitalisation due to an 
exacerbation of HF. Additionally, HF alone increases the 
risk of being affected by diabetes by around four times, 
while patients with diabetes are at a 2.5-fold higher risk 
of developing HF [1]. Interestingly, patients with diabetes 
have a 75% higher risk of death due to a cardiovascular 
event than the general population [1]. This indicates that 
diabetes and HF reciprocally induce each other’s deve-
lopment and worsen one another’s prognosis. Because of 
this, HF therapy has focused on the available drugs used 
in the treatment of diabetes and their potentially positive 
effect on the vascular system.
Diabetic cardiomyopathy
Diabetes affects the heart via several mechanisms. One of 
these is diabetic microangiopathy, which causes coronary 
artery disease and reduced blood flow to the heart muscle. 
Co-occurrence of diabetes in patients with HF worsens the 
diastolic function of the left ventricle (LV) by increasing its 
stiffness and mass. Diastolic dysfunction correlates with 
markers of insulin resistance, such as fasting glucose le-
vels, glycated haemoglobin and body mass index (BMI) [1]. 
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Diabetic cardiomyopathy is further classified into two 
types: restrictive cardiomyopathy, occurring more often 
in patients with type 2 diabetes and obesity, and dilated 
cardiomyopathy, which is more common with type 1 dia-
betes. Predisposing factors for restrictive cardiomyopathy 
can be hyperglycaemia, hyperinsulinemia and lipotoxicity, 
while autoimmunological processes accompany dilated 
cardiomyopathy.
The effect of diabetes  
on heart muscle metabolism
The heart muscle generates most of its energy from free 
fatty acids (FFAs) and glucose. However, due to the Randle 
cycle, the heart possesses a metabolic elasticity and is able 
to adapt to the body’s current metabolic abilities. In HF, the 
initial uptake of glucose and FFAs by cardiomyocytes incre-
ases, but their oxidation within mitochondria is decreased, 
leading to an accumulation of metabolic intermediates in 
the cytosol. In T2DM, increased levels of FFAs stimulate the 
proliferation of peroxisomes and elevated insulin resistance 
[1]. This minimises the use of glucose, thus reducing the 
metabolic elasticity of the heart muscle. The dominant use 
of FFAs in the hearts of diabetic patients contributes to 
a drop in effective energy production. This happens firstly 
because FFA oxidation requires higher amounts of oxygen 
than it would for glucose, and additionally because FFAs in-
duce the expression of uncoupling protein, leading to a loss 
of effective production of adenosine triposphate (ATP).
In diabetes, calorific need is estimated for elevated 
levels of FFAs and glucose. By contrast, in HF, sympathetic 
activation induces lipolysis and the release of FFAs from 
adipose tissue into the plasma. Elevated levels of FFAs are 
associated with worsened diastolic dysfunction.
Ketone bodies increase in response to energy deple-
tion or starvation, due to their function as an alternative 
energetic substrate. They are not directly available from 
the diet, but are instead produced by the liver over the 
course of incomplete oxidation of FFAs. Enzymes inducing 
the metabolic transformation of ketone bodies display 
an increased activity in HF, while those that inhibit this 
process remain scarce [1]. When this occurs, the failing 
heart oxidises ketone bodies as its main source of energy, 
while remaining metabolic pathways become compromised. 
Interestingly, ketone bodies induce the transport of FFAs to 
the adipose tissue, thus decreasing the concentration of 
circulating FFAs. This in turn increases the uptake of glu-
cose by cardiomyocytes, therefore increasing the efficiency 
of energy production.
Heart failure and insulin resistance
Insulin resistance, or the impaired ability of cells to take 
up glucose from circulation in response to insulin, is 
associated with lipolysis, lipogenesis and gluconeogenesis, 
increasing the supply of metabolic substrates to the heart 
muscle. However, overloading of the heart with these sub-
strates decreases the efficiency of their oxidation, leading 
to metabolic insufficiency, followed by myocardial failure 
due to lipotoxicity and glucotoxicity [1]. In this case, insu-
lin resistance of the heart muscle may serve as a kind of 
adaptive mechanism to reduce overloading with metabolic 
substrates.
Existing approaches to pharmacotherapy  
in patients with heart failure accompanied 
by diabetes
European Society of Cardiology (ESC) guidelines from 
2016 indicated only metformin as a treatment for patients 
with HF, but not due to functions improving the patients’ 
prognosis, but rather because metformin does not cause 
exacerbation of HF in this patient group. Metformin is 
a first-line treatment for type 2 diabetes, despite its me-
chanism of action not being fully known. It slows downs 
the process of gluconeogenesis by inhibiting respiratory 
enzymes. In addition to these metabolic changes, animal 
studies have shown that metformin prevents heart da-
mage following ischaemia, limiting the extent of a stroke 
and weakening post-ischaemic myocardial remodelling 
[1]. In addition, metformin improves endothelial function 
by limiting the production of peroxides and increasing 
the bioavailability of nitric oxide. It also strengthens the 
anti-inflammatory effect, weakening myocardial fibrosis. 
In one randomised trial, metformin reduced mortality 
and the incidence of ischaemic heart disease in diabetic 
patients, and these results were confirmed through 
a cohort study and a meta-analysis [1]. However, to date 
there have been no prospective studies raising the issue 
of using metformin in patients with both HF and diabetes. 
ESC guidelines from 2016 suggesting metformin as a first-
-line treatment in this patient group were based solely on 
a series of cohort studies which showed a slowed progres-
sion of HF and a smaller proportion of incidents of lactic 
acidosis in this patient group [2]. However, accompanying 
metformin therapy was not associated with a reduction 
in ischaemic area in the myocardium, or with improved 
diastolic ventricular function in diabetics with acute co-
ronary syndromes.
On the other hand, the use of exogenous insulin sti-
mulates the activity of the autonomic nervous system and 
causes an increase in vascular resistance, and hypertrophy 
of the myocardium and vasculature [3]. Moreover, over the 
course of using insulin, endothelial dysfunction occurs. The 
aforementioned changes are accompanied by a progres-
sion of HF and an increased risk of mortality. Insulin also 
retains sodium and causes water retention, which in HF pa - 
tients can cause exacerbation of the illness and oedema [4]. 
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Glitazones have similar side effects — especially in com-
bination with insulin, they cause fluid retention, oedemas, 
and increase in body mass (in 15% of those treated, this 
occurs within a week of commencing treatment, and may 
reach a 5 kg increase in body mass over six months) and 
pathologic fractures. During glitazone therapy, one can 
observe a temporary drop in haemoglobin concentration, 
a direct toxic effect on myocytes, and an unfavourable effect 
on the remodelling phenomenon [4]. Despite the literature 
containing data on the favourable effects of glitazones in 
patients with HF, such as the fact that they reduce vascu-
lar insulin resistance, lead to a reduction in afterload and 
additionally improve endothelial and myocardial function 
through improved glucose usage at the cost of decreasing 
the usage of FFAs, and lead to a regression in the hyper-
trophy of the heart muscle, their use in this patient group 
is highly risky [5].
Sodium-glucose co-transporter-2 inhibitors 
and glucagon-like peptide-1 agonists  
— a new approach  
in the cardiac patient population
In 2018, American College of Cardiology (ACC) recom-
mendations for the first time positioned sodium-glucose 
co-transporter-2 (SGLT-2) inhibitors and glucagon-like 
peptide-1 (GLP-1) agonists as drug classes that exhibit 
significant benefits in patients with HF and diabetes [5]. 
It was shown that the use of these compounds reduces 
negative cardiovascular effects in patients with diabetes, 
which initiated the development of a new treatment model 
not only in managing diabetes, but also in expanding this 
strategy into preventing cardiovascular events, which are 
the main cause of death in patients from this group. A simi-
lar position is presented by the American Heart Association 
(AHA). In the ACC/AHA guidelines for primary prevention of 
cardiovascular diseases published in 2019, SGLT2 inhibi-
tors and GLP-1 agonists may be consider for adults with 
diabetes type 2 and additional cardiovascular risk factors, 
who require glucose-lowering therapy despite initial lifestyle 
modifications and metformin to improve glycemic control 
and reduce cardiovascular risk [6].
SGLT-2 inhibitors are known as relatively new orally 
administered antidiabetic drugs used in the pharmacothe-
rapy of type 2 diabetes. Large randomised clinical studies 
conducted in patients with diabetes and accompanying 
cardiovascular disease showed that two drugs from this 
group — empagliflozin and kanagliflozin — reduce the 
frequency of cardiovascular events and the number of ho-
spitalisations due to heart failure (Table 1) [5]. Beyond the 
effects on blood glucose levels, these drugs cause increa-
sed excretion of sodium in urine and potentiate diuresis, 
reduce body mass, and decrease systolic blood pressure. 
This may be a result of their effects on the sympathetic 
nervous system and inhibition of sodium-hydrogen pumps, 
most likely reducing damage to the heart, hypertrophy, 
fibrosis, remodelling and systolic dysfunction [5]. This 
group may use an alternative metabolic pathway of the 
myocardium, using the oxidation of energetically richer 
ketone bodies instead of FFAs or glucose, which improves 
the functioning and efficiency of the heart muscle. It is 
also worth mentioning the recently published results of 
the DECLARE study [7]. This analysed the cardiovascular 
benefits in diabetic patients of using a different SGLT-2 in-
hibitor — dapagliflozin. It turned out that dapagliflozin did 
not affect the risk of cardiovascular events (MACE, defined 
as cardiovascular death, myocardial infarction or stroke), 
but did reduce mortality due to cardiovascular causes. 
A lower frequency of hospitalisations due to aggravations 
was also recorded [7].
When it comes to therapy using SGLT-2 inhibitors, 
side effects must be taken into account. One effect that 
is not very threatening, but causes more of a nuisance, 
is an increased risk of fungal infection. These are usually 
not very severe and are easily treated with antifungals. 
The literature has also described individual cases of an 
increased risk of ketoacidosis, which is why patients using 
SGLT-2 inhibitors are instructed that if they experience 
symptoms such as nausea, vomiting or abdominal pain, 
they should immediately stop taking the drugs and seek 
specialist advice [5]. This is also the case for empagliflozin, 
kanagliflozin and dapagliflozin, which is confirmed by the 
DECLARE study [7].
GLP-1 agonists have also demonstrated benefits for 
patients with HF and diabetes. In addition to lowering 
glucose levels by intensifying glucose-dependent insulin 
secretion and weakening glucagon production, and by 
slowing down stomach emptying, this drug group — as 
shown by the majority of clinical studies — reduces the risk 
of cardiovascular events (Table 2). This pertains mostly 
to long-acting GLP-1 agonists such as liraglutide. It has 
been documented that they lower systolic blood pressure 
from 1 to 6 mm Hg and reduce low-density lipoprotein 
(LDL) concentration. In animal studies, drugs from this 
group reduced the extent of ischaemia in acute coronary 
syndromes and improved myocardial function following 
reperfusion and decreased post-ischaemic remodelling 
of the LV. They improved LV function in HF patients mainly 
through increasing glucose consumption by cardiomyo-
cytes. In another study, these drugs decreased blood 
pressure by releasing atrial natriuretic peptide [5]. Positive 
cardiovascular effects were observed primarily in patients 
with a positive history of circulatory ailments, which is 
why they are recommended as a secondary prevention 
mechanism.
The main side effects relate to the digestive system — 
nausea and vomiting. A solution in this situation is to start 
with small doses of the drug and incrementally increase 
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Table 1. Summary of clinical trials of sodium-glucose co-transporter-2 inhibitors
Parameter EMPA-REG OUTCOME CANVAS/CANVAS–R DECLARE
Number of patients N = 7,020 N = 10,142 N = 17,160
Drug Empagliflozin Kanagliflozin Dapagliflozin
Dosage 10 or 25 mg p.o. daily 100 or 300 mg p.o. daily 10 mg p.o. daily
Mean observation time [years] 3.1 2.4 4.2
Baseline HbA1c [%] 8.1 8.2 8.3
Mean duration of diabetes [years] N/A* 13.5 10.5
Taking metformin [%] 74 77 82
Taking statin [%] 77 75 75
Incidence of cardiovascular disease [%] > 99 66 41
Primary endpoint** [HR (95% CI)] 0.86 (0.74–0.99) 0.86 (0.75–0.97) 0.83 (0.73–0.95)
Death due to CV [HR (95% CI)] 0.62 (0.49–0.77) 0.87 (0.72–1.06) 0.98 (0.82–1.17)
Episode of ACS (irrespective of conse-
quences) [HR (95% CI)]
0.87 (0.70–1.09) 0.89 (0.73–1.09) 0.89 (0.77–1.01)
Stroke (irrespective of consequences)  
[HR (95% CI)]
1.18 (0.89–1.56) 0.87 (0.69–1.09) 1.01 (0.84–1.21)
Overall mortality [HR (95% CI)] 0.68 (0.57–0.82) 0.87 (0.74–1.01) 0.93 (0.84–1.03)
Hospitalisation due to HF [HR (95% CI)] 0.65 (0.50–0.85) 0.67 (0.52–0.87) 0.73 (0.61–0.88)
*57% of patients with diabetes lasting > 10 years; **death due to CV causes, myocardial infarction not leading to death (excluding silent ischaemia); stroke not leading to death; p.o. — per os; HbA1c — glyca-
ted haemoglobin; HR — hazard ratio; CI — confidence interval; CV — cardiovascular; ACS — acute coronary syndrome; HF — heart failure
Table 2. Summary of clinical trials of glucagon-like peptide-1 agonists in the context of cardiovascular effects
Parameter LEADER SUSTAIN-6 EXS-CEL ELIXA
Number of patients 9,340 3,297 14,752 6,068
Drug Liraglutide Semaglutide Exenatide QW Lixisenatide
Dosage 1.8 mg or the maximal 
tolerate dose per day
0.5 mg or 1 mg 
weekly
2 mg weekly 10 µg or 20 µg 
daily
Mean observation time [years] 3.8 2.1 3.2 2.1
Baseline HbA1c [%] 8.7 8.7 8.0 7.7
Mean duration of diabetes [years] 12.8 13.9 12 9.3
Taking metformin [%] 76 73 77 66
Taking statin [%] 72 73 74 93
Incidence of cardiovascular disease 81/18 72/24 73.1/16.2 100/22
Primary endpoint* [HR (95% CI)] 0.87 (0.78–0.97) 0.74 (0.58–0.95) 0.91 (0.83–1.00) 1.02 (0.89–1.17)
Death due to CV [HR (95% CI)] 0.78 (0.66–0.93) 0.98 (0.65–1.48) 0.88 (0.76–1.02) 0.98 (0.78–1.22)
Episode of ACS (irrespective of conse-
quences) [HR (95% CI)]
0.86 (0.73–1.00) 0.74 (0.51–1.08) 0.97 (0.85–1.10) 1.03 (0.87–1.22)
Stroke (irrespective of consequences) 
[HR (95% CI)]
0.86 (0.71–1.06) 0.61 (0.38–0.99) 0.85 (0.70–1.03) 1.12 (0.79–1.58)
Overall mortality [HR (95% CI)] 0.85 (0.74–0.97) 1.05 (0.74–1.50) 0.86 (0.77–0.97) 0.94 (0.78–1.13)
Hospitalisation due to HF [HR (95% CI)] 0.87 (0.73–1.05) 1.11 (0.77–1.61) 0.94 (0.78–1.13) 0.96 (0.75–1.23)
*Death due to CV causes, myocardial infarction not leading to death (excluding silent ischaemia), stroke not leading to death; QW — quaque; HbA1c — glycated haemoglobin; HR — hazard ratio; CI — confiden-
ce interval; CV — cardiovascular; ACS — acute coronary syndrome; HF — heart failure
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Table 3. Recommended doses and indications for sodium-glucose co-transporter-2 inhibitors based on American College of Cardiology 
(ACC) 2018 experts’ statement [5] and ACC/American Heart Association (AHA) guidelines 2019 [6]
Parameter Empagliflozin Kanagliflozin Dapagliflozin [7]
Doses 10 mg p.o. daily 
25 mg p.o. daily
100 mg p.o. daily 
May be increased to 300 mg daily




Improved control of glycaemia in patients with 
DM2 
Reduction in risk of death due to cardiovascu-
lar causes in adult with DM2 and CV disease
Improved control of glycaemia in pa-
tients with DM2
Improved control of gly-




eGFR ≥ 45 mL/min/1.73 m2 — no change 
eGFR < 45 — do not increase dosage,  
discontinue if eGFR is stable low
eGFR ≥ 60 mL/min/1.73 m2 — no 
change 
eGFR 45–59 — do not exceed 100 mg 
per day 
eGFR < 45 — do not increase dosage, 
discontinue if eGFR continues to fall
eGFR < 60 mL/min/ 
/1.73 m2 — discontinue 
the drug therapy
p.o. — per os; FDA — Food and Drug Administration; DM2 — type 2 diabetes; CV — cardiovascular; eGFR — estimated glomerular filtration rate
Table 4. Recommended doses and indications for glucagon-like peptide-1 agonists
Parameter Liraglutide Semaglutide Lixisenatide Exenatide QW
Doses Initially 0.6 mg s.c. 
daily
Slowly increase to  
1.8 mg or maximal  
tolerated dose
Initially 0.25 mg s.c. 
weekly
Slowly increase to ma-
ximal tolerated dose
10 µg s.c. daily
Increase, if tolerated, 
to 20 µg daily
2 mg s.c. weekly
Indications approved 
by the FDA
Improved control of 
glycaemia in patients 
with DM2
Reduced risk of MI, 
CVA and death due 
to CV in patients with 
DM2 and CV disease
Improved control of 
glycaemia in patients 
with DM2
Improved control of 
glycaemia in patients 
with DM2
Improved control of  
glycaemia in patients  
with DM2
Dose modification Increase slowly to 




No need to change 
dosage in the case of 
impaired kidney or liver 
function
Increase slowly to 




No need to change 
dosage in the case of 
impaired kidney or liver 
function
Increase slowly to 




CrCL ≥ 30 mL/min — 
do not change dosage
CrCL 15–29 — monitor 
kidney function
CrCL < 15 — do not use
Discontinue if pancreati-
tis is suspected
CrCL ≥ 60 mL/min — do 
not change dosage
CrCL 30–59 — close ob-
servation
CrCL < 30 — do not use
s.c. — subcutaneously; FDA — Food and Drug Administration; DM2 — type 2 diabetes; MI — myocardial infarction; CVA — cerebrovascular accident; CV — cardiovascular; CrCL — creatinine clearance
the dosage, while educating the patient about the size of 
consumed meals. GLP-1 agonists can also increase the 
incidence of cholecystitis, acute pancreatitis or pancreatic 
cancer. However, to date a definitive correlation between 
the use of these drugs and the mentioned conditions has 
not been proven [5].
A new therapeutic model for patients  
with HF and diabetes mellitus 
Based on the update on HF 2019 is SGLT2 inhibitors should 
be consider in patients with cardiovascular disease and in 
patients with high cardiovascular risk to prevent or delay the 
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Figure 1. Treatment protocol according to American College of Cardiology (ACC) 2018 for antidiabetic drug therapy (based on [5]); ASCVD — 
atherosclerotic cardiovascular disease; DM2 — type 2 diabetes; SGLT-2 — sodium-glucose co-transporter-2; GLP-1 — glucagon-like peptide-1
GLP-1 agonists should be informed about possible dige-
stive symptoms, such as nausea and vomiting, which do 
not indicate a pathology, but become self-limiting over 
time (Figure 1) [5]. 
Summary
The development of pharmacotherapy in diabetes and ad-
ditional positive effect on the cardiovascular system of two 
drug groups — SGLT2 inhibitors and GLP-1 agonists — give 
completely new look on the population with heart failure 
and co-existing diabetes. The current challenge for specia-
lists is to implement the therapy according to the ACC 2018 
scheme. The new antidiabetic drugs are in the 2019 ACC/ 
/AHA guidelines for primary prevention for cardiovascular 
diseases. It should be emphasize many trials with SGLT2 
inhibitors are ongoing in HF with and without diabetes as 
co-existing disease.
Conflict(s) of interest
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onset of HF or HF hospitalization [8]. When commencing 
therapy with SGLT-2 inhibitors, in which the most recom-
mended drug is currently empagliflozin, treatment should 
begin with lowest available dose. Increasing the dosage 
is not necessary to maintain a favourable cardiovascular 
effect, however it should be noted that it can be increased 
due to non-cardiac causes (Table 3). Among GLP-1 ago-
nists, the currently most promising drug in clinical trials is 
liraglutide. Therapy with this drug should be started with 
a minimal dose, which should be incrementally increased 
to a maximum tolerated dose, bearing in mind that the the-
rapeutic concentration for the reduction of cardiovascular 
risk is 1.18 mg per day (Table 4).
Patients starting SGLT-2 inhibitor therapy should be 
informed about the previously mentioned side effects. 
In addition, due to increased diuresis, which may be 
exacerbated by any simultaneously used loop diuretics, 
patients must monitor for symptoms of dehydration, 
such as orthostatic hypotension. SGLT-2 inhibitors can 
also decrease eGFR levels, which is why it is worthwhile 
to control for kidney function in the first few weeks of 
introducing the drug. Patients commencing therapy with 
End-stage renal failure? 
Pregnancy? Breastfeeding?
Do not begin SGLT-2 inhibitor 
and GLP-1 agonist therapy
Is the patient > 18 years-old and 
suffer from ASCVD and DM2?
Yes Yes
No No
Consider introducing SGLT-2 
inhibitors/GLP-1 agonists
Insufficient indications 
for the use of SGLT-2 
inhibitors/GLP-1 agonists
Consider indications, therapeutic 
goals and patient co-operation
SGLT-2 inhibitorThe patient does not want 
to start therapy with an SGLT-2
 inhibitor or GLP-1 agonist
GLP-1 agonist
Empagliflozin as a first-choice drug
Does not require increased dosage
Adjust other antidiabetic 
medication as recommended
Liraglutide as a first-choice drug
Slowly increase the dosage
Adjust other antidiabetic 
medication as recommended
Monitor the response to therapy Monitor the response to therapy
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Streszczenie
Niewydolność serca (HF), mimo wprowadzenia złożonych modeli farmakoterapii, wciąż stanowi wyzwanie terapeutycz-
ne, zwłaszcza gdy współtowarzyszy jej cukrzyca. W ostatnim czasie wyniki dużych badań klinicznych wykazały liczne 
korzyści ze stosowania inhibitorów kotransportera glukozowo-sodowego 2 i analogów glukagonopodobnego peptydu 1 
jako leków nie tylko przeciwcukrzycowych, ale i obniżających ryzyko wystąpienia zdarzeń sercowo-naczyniowych oraz 
częstość hospitalizacji z powodu zaostrzeń HF. Znalazło to odzwierciedlenie w ostatnich wytycznych American College 
of Cardiology (ACC) z 2018 roku dotyczących ryzyka u pacjentów z cukrzycą i chorobami układu sercowo-naczyniowego 
oraz najnowszych wytycznych ACC/American Heart Association (AHA) z 2019 roku poświęconych prewencji pierwotnej 
chorób układu sercowo-naczyniowego.
Słowa kluczowe: niewydolność serca, cukrzyca, farmakoterapia   
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